HSV-2: In pursuit of a vaccine

Journal of Clinical Investigation

Volumn 121, Issue 12, 2011, Pages 4600-4609

  Johnston, Christine ^a,b   Koelle, David M ^a,b,c   Wald, Anna ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; HERPES SIMPLEX VACCINE; HERPES SIMPLEX VIRUS 2 VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEUTRALIZING ANTIBODY; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE ICP0; UNCLASSIFIED DRUG;

ABRASION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOKINE RELEASE; DRUG EFFICACY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HERPES SIMPLEX VIRUS 2 INFECTION; HIGH RISK POPULATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOGENICITY; IMMUNOSTIMULATION; INNATE IMMUNITY; INOCULATION; LYMPHOCYTIC INFILTRATION; NONHUMAN; PHOSPHORYLATION; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROSTITUTION; PROTEIN PROTEIN INTERACTION; REVIEW; SEROCONVERSION; SEXUAL TRANSMISSION; SPINAL GANGLION; VACCINATION; VIRUS LATENCY; VIRUS PATHOGENESIS; VIRUS REACTIVATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

ANIMALS; ANTIBODIES, VIRAL; COMORBIDITY; DISEASE MODELS, ANIMAL; FEMALE; FORECASTING; GANGLIA, SPINAL; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HERPESVIRUS VACCINES; HIV INFECTIONS; HUMANS; IMMUNE EVASION; IMMUNITY, MUCOSAL; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROEPIDEMIOLOGIC STUDIES; VACCINATION; VIRUS LATENCY; YOUNG ADULT;

EID: 84055193947     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI57148     Document Type: Review

References (150)

1. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ. 2008;86(10):805-812.
2. Center for Disease Control and Prevention. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. MMWR Morb Mortal Wkly Rep. 2010;59(15):456-459.
3. Paz-Bailey G, Ramaswamy M, Hawkes SJ, Geretti AM. Herpes simplex virus type 2: epidemiology and management options in developing countries. Sexually Transmitted Infections. 2007;83(1):16-22. (Pubitemid 46293800)
4. Xu F, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296(8):964-973. (Pubitemid 44285373)
5. Mertz KJ, et al. Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis. 1998;178(6):1795-1798. (Pubitemid 28558157)
6. Paz-Bailey G, et al. Changes in the etiology of sexually transmitted diseases in Botswana between 1993 and 2002: implications for the clinical management of genital ulcer disease. Clin Infect Dis. 2005;41(9):1304-1312. (Pubitemid 41532674)
7. Xu F, et al. Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994. J Infect Dis. 2002;185(8):1019-1024. (Pubitemid 34297758)
8. Mertz GJ, Benedetti J, Ashley R, Selke SA, Corey L. Risk factors for the sexual transmission of genital herpes. Ann Intern Med. 1992;116(3):197-202.
9. Wald A, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med. 2000;342(12):844-850. (Pubitemid 30165207)
10. Yorke JA, Hethcote HW, Nold A. Dynamics and control of the transmission of gonorrhea. Sex Transm Dis. 1978;5(2):51-56.
11. Ryder N, Jin F, McNulty AM, Grulich AE, Donovan B. Increasing role of herpes simplex virus type 1 in first-episode anogenital herpes in heterosexual women and younger men who have sex with men, 1992-2006. Sex Transm Infect. 2009;85(6):416-419.
12. Brown ZA, Wald A, Morrow RA, Selke S, Zeh J, Corey L. Effect of serologic status and cesarean delivery on transmission rates of herpes simplex virus from mother to infant. Jama. 2003;289(2):203-209. (Pubitemid 36068708)
13. Looker KJ, Garnett GP. A systematic review of the epidemiology and interaction of herpes simplex virus types 1 and 2. Sex Transm Infect. 2005;81(2):103-107. (Pubitemid 40523818)
14. Balachandran N, Oba DE, Hutt-Fletcher LM. Antigenic cross-reactions among herpes simplex virus types 1 and 2, Epstein-Barr virus, and cytomegalovirus. J Virol. 1987;61(4):1125-1135. (Pubitemid 17044026)
15. Ford CA, English A, Davenport AF, Stinnett AJ. Increasing adolescent vaccination: barriers and strategies in the context of policy, legal, and financial issues. J Adolesc Health. 2009;44(6):568-574.
16. Brown ZA, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997;337(8):509-515. (Pubitemid 27352016)
17. Kimberlin DW, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics. 2001;108(2):223-229.
18. Dinh T-H, Dunne EF, Markowitz LE, Weinstock H, Berman S. Assessing Neonatal Herpes Reporting in the United States, 2000-2005. Sex Transm Dis. 2008;35(1):19-21. (Pubitemid 351619347)
19. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS. 2006;20(1):73-83. (Pubitemid 41818117)
20. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis. 2002;185(1):45-52. (Pubitemid 34043015)
21. Zhu J, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med. 2009;15(8):886-892.
22. Freeman EE, et al. Population-level effect of potential HSV2 prophylactic vaccines on HIV incidence in sub-Saharan Africa. Vaccine. 2009;27(6):940-946.
23. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010;59(RR-12):1-110.
24. Wald A, Krantz E, Selke S, Lairson E, Morrow RA, Zeh J. Knowledge of partners' genital herpes protects against herpes simplex virus type 2 acquisition. J Infect Dis. 2006;194(1):42-52.
25. Martin ET, et al. A pooled analysis of the effect of condoms in preventing HSV-2 acquisition. Arch Intern Med. 2009;169(13):1233-1240.
26. Corey L, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med. 2004;350(1):11-20. (Pubitemid 38032179)
27. Celum C, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 371(9630):2109-2119. (Pubitemid 351902179)
28. Watson-Jones D, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med. 2008;358(15):1560-1571. (Pubitemid 351519816)
29. Celum C, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362(5):427-439.
30. Cunningham AL, et al. The cycle of human herpes simplex virus infection: virus transport and immune control. J Infect Dis. 2006;194 suppl 1:S11-S18. (Pubitemid 44420867)
31. Mark K, et al. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J Infect Dis. 2008;198(8):1141-1149.
32. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J Clin Invest. 1997;99(5):1092-1097. (Pubitemid 27123647)
33. Tronstein E, et al. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA. 2011;305(14):1441-1449.
34. Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995;333(12):770-775.
35. Crespi CM, Cumberland WG, Wald A, Corey L, Blower S. Longitudinal study of herpes simplex virus type 2 infection using viral dynamic modelling. Sex Transm Infect. 2007;83(5):359-364. (Pubitemid 47242482)
36. Schiffer JT, et al. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med. 2009;1(7):7ra16.
37. Tata S, et al. Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J Infect Dis. 2010;201(4):499-504.
38. Zhu J, et al. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med. 2007;204(3):595-603. (Pubitemid 46457082)
39. Johnson KE, et al. Effects of HIV-1 and herpes simplex virus type 2 infection on lymphocyte and dendritic cell density in adult foreskins from Rakai, Uganda. J Infect Dis. 2011;203(5):602-609.
40. Watson-Jones D, et al. Risk factors for herpes simplex virus type 2 and HIV among women at high risk in northwestern Tanzania: preparing for an HSV-2 intervention trial. J Acquir Immune Defic Syndr. 2007;46(5):631-642. (Pubitemid 350191058)
41. Prichard MN, et al. Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine. 2005; 23(46-47):5424-5431. (Pubitemid 41579315)
42. Posavad CM, et al. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J Immunol. 2010;184(6):3250-3259.
43. Lakeman AD, Nahmias AJ, Whitley RJ. Analysis of DNA from recurrent genital herpes simplex virus isolates by restriction endonuclease digestion. Sex Transm Dis. 1986;13(2):61-66. (Pubitemid 17212094)
44. Schmidt OW, Fife KH, Corey L. Reinfection is an uncommon occurrence in patients with symptomatic recurrent genital herpes. J Infect Dis. 1984;149(4):645-646. (Pubitemid 14139054)
45. Roest RW, et al. Genotypic analysis of sequential genital herpes simplex virus type 1 (HSV-1) isolates of patients with recurrent HSV-1 associated genital herpes. J Med Virol. 2004;73(4):601-604. (Pubitemid 38857212)
46. Roest RW, Maertzdorf J, Kant M, van der Meijden WI, Osterhaus AD, Verjans GM. High incidence of genotypic variance between sequential herpes simplex virus type 2 isolates from HIV-1-seropositive patients with recurrent genital herpes. J Infect Dis. 2006;194(8):1115-1118. (Pubitemid 44547651)
47. Novak Z, et al. Cytomegalovirus Strain Diversity in Seropositive Women. J Clin Microbiol. 2008;46(3):882-886. (Pubitemid 351379973)
48. Watson-Jones D, et al. Acyclovir suppression for HIV prevention is not associated with genotypic evidence of acyclovir resistance to HSV-2: Analysis of specimens from three phase III trials [published online ahead of print August 11, 2010]. J Clin Microbiol. doi:10.1128/JCM.01263-10.
49. Burrel S, Deback C, Agut H, Boutolleau D. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. Antimicrob Agents Chemother. 2010;54(11):4833-4842.
50. Koelle DM, Posavad CM, Barnum GR, Johnson ML, Frank JM, Corey L. Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest. 1998;101(7):1500-1508. (Pubitemid 28166848)
51. Siegal FP, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 1981;305(24):1439-1444. (Pubitemid 12240078)
52. Naraqi S, Jackson GG, Jonasson O, Yamashiroya HM. Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. J Infect Dis. 1977;136(4):531-540. (Pubitemid 8211385)
53. Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis. 1980;142(3):338-346. (Pubitemid 10024569)
54. Donaghy H, et al. Role for plasmacytoid dendritic cells in the immune control of recurrent human herpes simplex virus infection. J Virol. 2009;83(4):1952-1961.
55. Lund JM, Linehan MM, Iijima N, Iwasaki A. Cutting edge: Plasmacytoid dendritic cells provide innate immune protection against mucosal viral infection in situ. J Immunol. 2006;177(11):7510-7514. (Pubitemid 44846264)
56. Kurt-Jones EA, et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc Natl Acad Sci U S A. 2004;101(5):1315-1320. (Pubitemid 38182686)
57. Zhang S-Y, et al. TLR3 deficiency in patients with herpes simplex encephalitis. Science. 2007; 317(5844):1522-1527. (Pubitemid 47417427)
58. Ishikawa H, Ma Z, Barber GN. STING regulates intracellular DNA-mediated, type I interferon- dependent innate immunity. Nature. 2009;461(7265):788-792.
59. Casrouge A, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science. 2006;314(5797):308-312. (Pubitemid 44571977)
60. Casanova JL, Abel L, Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu Rev Immunol. 2011;29:447-491.
61. Herbst-Kralovetz MM, Pyles RB. Quantification of poly(I:C)-mediated protection against geni tal herpes simplex virus type 2 infection. J Virol. 2006;80(20):9988-9997. (Pubitemid 44522593)
62. Mark KE, et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis. 2007;195(9):1324-1331. (Pubitemid 46649619)
63. Bochud PY, Magaret AS, Koelle DM, Aderem A, Wald A. Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex type 2 infection. J Infect Dis. 2007;196(4):505-509. (Pubitemid 47206095)
64. Peng T, et al. Evasion of the mucosal innate immune system by herpes simplex virus type 2. J Virol. 2009;83(23):12559-12568.
65. Melroe GT, DeLuca NA, Knipe DM. Herpes Simplex Virus 1 has multiple mechanisms for blocking virus-induced interferon production. J Virol. 2004; 78(16):8411-8420. (Pubitemid 39025107)
66. van Lint AL, et al. Herpes Simplex Virus immediateearly ICP0 protein inhibits toll-like receptor 2-dependent inflammatory responses and NF-{kappa}B signaling. J Virol. 2010;84(20):10802-10811.
67. Schacker T, Zeh J, Hu HL, Hill E, Corey L. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J Infect Dis. 1998;178(6):1616-1622. (Pubitemid 28558132)
68. Finke JS, Shodell M, Shah K, Siegal FP, Steinman RM. Dendritic cell numbers in the blood of HIV-1 infected patients before and after changes in antiretroviral therapy. J Clin Immunol. 2004;24(6):647-652. (Pubitemid 40933116)
69. Morrison LA. Replication-defective virus vaccine-induced protection of mice from genital herpes simplex virus 2 requires CD4 T cells. Virology. 2008;376(1):205-210.
70. Iijima N, et al. Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J Exp Med. 2008;205(13):3041-3052.
71. Simmons A, Tshcharke DC. Anti-CD8 impairs clearance of herpes simplex virus from the nervous system: implications for the fate of virally infected neurons. J Exp Med. 1992;175(5):1337-1344.
72. Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, Hendricks RL. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science. 2008;322(5899):268-271.
73. Verjans GMGM, et al. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A. 2007;104(9):3496-3501. (Pubitemid 46364187)
74. Schiffer JT, et al. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc Natl Acad Sci U S A. 2010;107(44):18973-18978.
75. Hosken N, et al. Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J Virol. 2006;80(11):5509-5515.
76. Cohen GH, et al. Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody. J Virol. 1984;49(1):102-108. (Pubitemid 14207147)
77. Brown ZA, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. N Engl J Med. 1991;324(18):1247-1252.
78. Bourne N, Pyles RB, Bernstein DI, Stanberry LR. Modification of primary and recurrent genital herpes in guinea pigs by passive immunization. J Gen Virol. 2002;83(pt 11):2797-2801. (Pubitemid 35276980)
79. Mester JC, Glorioso JC, Rouse BT. Protection against zosteriform spread of herpes simplex virus by monoclonal antibodies. J Infect Dis. 1991; 163(2):263-269.
80. Taylor JM, et al. Alternative entry receptors for herpes simplex virus and their roles in disease. Cell Host Microbe. 2007;2(1):19-28. (Pubitemid 47010244)
81. Heldwein EE, Lou H, Bender FC, Cohen GH, Eisenberg RJ, Harrison SC. Crystal structure of glycoprotein B from herpes simplex virus 1. Science. 2006;313(5784):217-220. (Pubitemid 44066251)
82. Chowdary TK, Cairns TM, Atanasiu D, Cohen GH, Eisenberg RJ, Heldwein EE. Crystal structure of the conserved herpesvirus fusion regulator complex gH-gL. Nat Struct Mol Biol. 2010;17(7):882-888.
83. Carfi A, et al. Herpes simplex virus glycoprotein D bound to the human receptor HveA. Molecular Cell. 2001;8(1):169-179. (Pubitemid 32772915)
84. Perng G-C, et al. Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science. 2000;287(5457):1500-1503. (Pubitemid 30127146)
85. Jerome KR, Fox R, Chen Z, Sears AE, Lee H-y, Corey L. Herpes simplex virus inhibits apoptosis through the action of two genes, Us5 and Us3. J Virol. 1999;73(11):8950-8957. (Pubitemid 29487047)
86. Sloan DD, Jerome KR. Herpes simplex virus remodels T-cell receptor signaling, resulting in p38-dependent selective synthesis of interleukin- 10. J Virol. 2007;81(22):12504-12514. (Pubitemid 350085864)
87. Fruh K, et al. A viral inhibitor of peptide transporters for antigen presentation. Nature. 1995; 375(6530):415-418.
88. Cotter CR, Nguyen ML, Yount JS, Lopez CB, Blaho JA, Moran TM. The virion host shut-off (vhs) protein blocks a tlr-independent pathway of herpes simplex virus type 1 recognition in human and mouse dendritic cells. PLoS One. 2010;5(2):e8684.
89. Hoshino Y, et al. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5- 29-41L in mice and guinea pigs. Vaccine. 2008; 26(32):4034-4040.
90. Thomas S, Barton S, Reay P, Marshall T, Love C, Goldsweig H, Coffin RS. Clinical development of an immune evasion gene-deleted live attenuated vaccine for HSV-2 (ImmunoVEX HSV2). 35th International Herpesvirus Workshop. Salt Lake City, Utah, USA. September 12, 2010.
91. Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL. Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity. 2003;18(5):593-603. (Pubitemid 36588577)
92. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat Immunol. 2009;10(5):524-530.
93. Scriba M. Recurrent genital Herpes simplex virus (HSV) infection of guinea pigs. Med Microbiol Immunol. 1976;162(3-4):201-208.
94. Yim KC, et al. The cotton rat provides a novel model to study genital herpes infection and to evaluate preventive strategies. J Virol. 2005;79(23):14632-14639. (Pubitemid 41636262)
95. Lekstrom-Himes JA, Pesnicak L, Straus SE. The quantity of latent viral DNA correlates with the relative rates at which herpes simplex virus types 1 and 2 cause recurrent genital herpes outbreaks. J Virol. 1998;72(4):2760-2764. (Pubitemid 28175512)
96. Bourne N, Milligan GN, Stanberry LR, Stegall R, Pyles RB. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis. 2005;192(12):2117-2123. (Pubitemid 41779210)
97. Bernstein DI, et al. Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig. Vaccine. 2011;29(11):2071-2078.
98. Magaret A Johnston C, Wald A. Use of the designation "shedder" in mucosal detection of herpes simplex virus DNA involving repeated sampling. Sex Transm Infect. 2009;85(4):270-275.
99. Morgan C, et al. The use of nonhuman primate models in HIV vaccine development. PLoS Med. 2008;5(8):e173.
100. Corey L, et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. Jama. 1999;282(4):331-340. (Pubitemid 29350487)
101. Langenberg AG, et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. Ann Intern Med. 1995;122(12):889-898.
102. Bernstein DI, et al. Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis. 2005;40(9):1271-1281. (Pubitemid 40570236)
103. Stanberry LR, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med. 2002;347(21):1652-1661. (Pubitemid 35340783)
104. Cohen J. Painful failure of promising genital herpes vaccine. Science. 2010;330(6002):304-304.
105. Garnett GP, Dubin G, Slaoui M, Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect. 2004; 80(1):24-29. (Pubitemid 38221892)
106. Straus SE, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet. 1994;343(8911):1460-1463. (Pubitemid 24176334)
107. Straus SE, et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. J Infect Dis. 1997;176(5):1129-1134. (Pubitemid 27460974)
108. Oxman MN. Zoster vaccine: current status and future prospects. Clin Infect Dis. 2010;51(2):197-213.
109. Weinberg A, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009;200(7):1068-1077.
110. Casanova G, et al. A double-blind study of the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis. 2002;70(4):235-239.
111. de Bruyn G, et al. A randomized controlled trial of a replication defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent genital herpes among immunocompetent subjects. Vaccine. 2006;24(7):914-920.
112. Brans R, Yao F. Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs. BMC Microbiol. 2010;10:163.
113. Hoshino Y, et al. Protection from Herpes Simplex Virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1- seropositive and HSV-1-seronegative guinea pigs. J Infect Dis. 2009;200(7):1088-1095.
114. Brittle EE, Wang F, Lubinski JM, Bunte RM, Friedman HM. A replication-competent, neuronal spreaddefective, live attenuated herpes simplex virus type 1 vaccine. J Virol. 2008;82(17):8431-8441.
115. Halford WP, Puschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B. A live-attenuated HSV-2 ICP0- virus elicits 10 to 100 times greater protection against genital herpes than a glycoprotein D subunit vaccine. PLoS ONE. 2011;6(3):e17748.
116. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev. 2003;16(1):96-113. (Pubitemid 36114709)
117. Parr EL, Parr MB. Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2. J Virol. 1998;72(6):5137-5145. (Pubitemid 28215695)
118. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04- adjuvanted HPV-16/18 vaccine: Improving upon nature. Gynecol Oncol. 2008;110(3 suppl 1):S1-S10.
119. Garland SM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Eng J Med. 2007;356(19)1928-1943. (Pubitemid 46740303)
120. Schwartz EJ, Blower S. Predicting the potential individual- and population-level effects of imperfect herpes simplex virus type 2 vaccines. J Infect Dis. 2005;191(10):1734-1746. (Pubitemid 40656763)
121. Alsallaq RA, Schiffer JT, Longini IM Jr, Wald A, Corey L, Abu-Raddad LJ. Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2. Sex Transm Dis. 2010;37(5):290-297.
122. Schwartz EJ, Bodine EN, Blower S. Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines. Hum Vaccin. 2007;3(6):231-238.
123. Barouch DH, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science. 2000;290(5491):486-492.
124. Mertz GJ, et al. Herpes simplex virus type-2 glycoprotein-subunit vaccine: tolerance and humoral and cellular responses in humans. J Infect Dis. 1984;150(2):242-249. (Pubitemid 14073365)
125. Mertz GJ, et al. Double-blind, placebo-controlled trial of a herpes simplex virus type 2 glycoprotein vaccine in persons at high risk for genital herpes infection. J Infect Dis. 1990;161(4):653-660. (Pubitemid 20120221)
126. NIAID/NIH. Study finds genital herpes vaccine ineffective in women. NIAID web site. http://www. niaid.nih.gov/news/newsreleases/2010/Pages/Herpevac.aspx. Accessed October 14, 2011.
127. Cattamanchi A, et al. Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system. Clin Vaccine Immunol. 2008;15(11):1638-1643.
128. Koelle DM, et al. Phase I dose-escalation study of a monovalent heat shock protein 70-herpes simplex virus type 2 (HSV-2) peptide-based vaccine designed to prime or boost CD8 T-cell responses in HSV-naïve and HSV-2-infected subjects. Clin Vaccine Immunol. 2008;15(5):773-782. (Pubitemid 351967022)
129. Kutinova L, et al. Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences. Vaccine. 1988;6(3):223-228.
130. Skinner GR, et al. The efficacy and safety of Skinner herpes simplex vaccine towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial. Med Microbiol Immunol. 1997;186(1):31-36. (Pubitemid 27303410)
131. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis. 1988;158(3):602-614.
132. Spector FC, et al. Evaluation of a live attenuated recombinant virus RAV 9395 as a herpes simplex virus type 2 vaccine in guinea pigs. J Infect Dis. 1998;177(5):1143-1154. (Pubitemid 28194250)
133. Wachsman M, Kulka M, Smith CC, Aurelian L. A growth and latency compromised herpes simplex virus type 2 mutant (ICP10[Delta]PK) has prophylactic and therapeutic protective activity in guinea pigs. Vaccine. 2001;19(15-16):1879-1890. (Pubitemid 32178335)
134. McLean CS, Ni Challanain D, Duncan I, Boursnell ME, Jennings R, Inglis SC. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine. Vaccine. 1996;14(10):987-992. (Pubitemid 26271072)
135. Boursnell ME, et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J Infect Dis. 1997;175(1):16-25. (Pubitemid 27020819)
136. Da Costa XJ, Bourne N, Stanberry LR, Knipe DM. Construction and characterization of a replicationdefective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology. 1997;232(1):1-12. (Pubitemid 27244457)
137. Hoshino Y, et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol. 2005;79(1):410-418. (Pubitemid 39648394)
138. Heineman TC, Connelly BL, Bourne N, Stanberry LR, Cohen J. Immunization with recombinant varicellazoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. J Virol. 1995;69(12):8109-8113. (Pubitemid 3004502)
139. Bernstein DI. Effect of route of vaccination with vaccinia virus expressing HSV-2 glycoprotein D on protection from genital HSV-2 infection. Vaccine. 2000;18(14):1351-1358. (Pubitemid 30017847)
140. Natuk RJ, et al. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J Virol. 2006;80(9):4447-4457.
141. Bourne N, Stanberry LR, Bernstein DI, Lew D. DNA immunization against experimental genital herpes simplex virus infection. J Infect Dis. 1996;173(4):800-807. (Pubitemid 26176001)
142. McClements WL, Armstrong ME, Keys RD, Liu MA. The prophylactic effect of immunization with DNA encoding herpes simplex virus glycoproteins on HSV-induced disease in guinea pigs. Vaccine. 1997;15(8):857-860. (Pubitemid 27287975)
143. Mester JC, Twomey TA, Tepe ET, Bernstein DI. Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C. Vaccine. 1999;18(9-10):875-883.
144. Fotouhi F, Soleimanjahi H, Roostaee MH, Behzadian F. Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting. FEMS Immunol Med Microbiol. 2008;54(1):18-26.
145. Morello CS, Levinson MS, Kraynyak KA, Spector DH. Immunization with herpes simplex virus 2 (HSV-2) genes plus inactivated HSV-2 is highly protective against acute and recurrent HSV-2 disease. J Virol. 2011;85(7):3461-3472.
146. O'Hagan D, Goldbeck C, Ugozzoli M, Ott G, Burke RL. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs. Vaccine. 1999;17(18):2229-2236. (Pubitemid 29225674)
147. Simms JR, Heath AW, Jennings R. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs. J Infect Dis. 2000;181(4):1240-1248. (Pubitemid 30252527)
148. Bourne N, et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis. 2003;187(4):542-549. (Pubitemid 36250017)
149. Quenelle DC, Collins DJ, Marciani DJ, Kern ER. Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2. Vaccine. 2006;24(10):1515-1522. (Pubitemid 43238225)
150. Bernstein DI, et al. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine. 2010; 28(21):3748-3753.